Cyclacel Pharmaceuticals, Inc. (CYCC) At $1.78 Forms Bottom; Nuveen Diversified Dividend & Income Fund (JDD) Sentiment Is 2.13

Nuveen Diversified Dividend and Income Fund is a closed-ended balanced mutual fund launched by Nuveen Investments Inc. The company has market cap of $245.39 million. The fund is co-managed by Nuveen Fund Advisors, LLC, NWQ Investment Management Company, LLC, Security Capital Research & Management Incorporated, Symphony Asset Management LLC, and Wellington Management Company LLP. It has a 11.21 P/E ratio. It invests in public equity and fixed income markets across the globe.

Cyclacel Pharmaceuticals, Inc. (CYCC) formed multiple bottom with $1.73 target or 3.00% below today’s $1.78 share price. Cyclacel Pharmaceuticals, Inc. (CYCC) has $21.19M valuation. The stock increased 1.71% or $0.03 during the last trading session, reaching $1.78. About 264,459 shares traded. Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) has risen 10.62% since January 29, 2017 and is uptrending. It has underperformed by 6.08% the S&P500.

Advisors Asset Management Inc. holds 0.09% of its portfolio in Nuveen Diversified Dividend and Income Fund for 398,876 shares. Clenar Muke Llc owns 100,469 shares or 0.06% of their US portfolio. Moreover, Ifc Holdings Incorporated Fl has 0.04% invested in the company for 43,340 shares. The Illinois-based Pekin Singer Strauss Asset Management Il has invested 0.03% in the stock. Advisory Services Network Llc, a Georgia-based fund reported 4,200 shares.

The stock increased 0.00% or $0.0001 during the last trading session, reaching $12.4301. About 61,777 shares traded. Nuveen Diversified Dividend and Income Fund (JDD) has risen 14.19% since January 29, 2017 and is uptrending. It has underperformed by 2.51% the S&P500.

Investors sentiment decreased to 0 in Q3 2017. Its down Infinity, from Infinity in 2017Q2. It dropped, as 0 investors sold Cyclacel Pharmaceuticals, Inc. shares while 0 reduced holdings. 0 funds opened positions while 0 raised stakes. 13,295 shares or 0.00% without change from 13,295 shares in 2017Q2 were reported. Baker Bros Lp reported 13,253 shares or 0% of all its holdings. Tower Cap Limited Co (Trc) holds 0% in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) or 42 shares.